ArticleBMC psychiatry2025
Rehospitalization risk in community-dwelling schizophrenia patients receiving paliperidone palmitate: a retrospective cohort study in urban China.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundWhile long-acting injectable paliperidone palmitate (PP-LAI) improves treatment adherence in schizophrenia, rehospitalization risks persist under community management. This study identified factors influencing rehospitalization in community-dwelling schizophrenia patients receiving PP-LAI.
methodsA retrospective cohort study included 560 patients from 124 communities in Shenzhen (16 September 2022-15 September 2024). Data were extracted from medical databases. The primary outcome was rehospitalization due to psychiatric relapse. Multivariate Cox regression models were used to identify independent risk factors, adjusting for covariates including age, gender, marital status, employment, guardian relationship, pre-study hospitalization history, treatment phase, and concomitant antipsychotic use.
resultsDuring a median follow-up of 14 months, 50 patients (8.93%) were rehospitalized (rate: 7.83 per 100 person-year). Treatment discontinuation (n = 133) was primarily due to adverse drug reactions (30.08%) and disease relapse (31.58%). Cox analysis identified guardian type (parents vs. spouse: HR = 2.14, 95% CI: 1.05-4.37), pre-study hospitalization history (yes vs. no: HR = 2.69, 95% CI: 1.50-4.81), and treatment discontinuity (discontinuation vs. regular treatment: HR = 8.61, 95% CI: 2.61-28.35) as independent risk factors for rehospitalization.
conclusionsSensitivity analysis suggested that the elevated risk was substantially driven by patients who discontinued treatment due to disease relapse, indicating a complex interplay between discontinuation and outcome. Prior hospitalization and guardianship by parents also significantly increase risks. Clinical strategies should prioritize maintaining treatment continuity, proactively managing side effects, and strengthening family/community support for high-risk groups to reduce the risk of rehospitalization.
trial registrationNot applicable. (This is a retrospective observational study and does not involve a clinical trial requiring prospective registration).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.